A treatment with Fulvestrant and Exemestane in postmenopausal patients with advanced hormone receptor–positive (HR) + breast cancer - ACT-FASTER:

Inclusion Criteria

• Inclusion Criteria:
• - Signed written informed consent
• - Female postmenopausal patient (or patient post-ovariectomy) and age ≥18 years
• Postmenopause ist defined as
• • Age ≥ 60 years and natural menopause with menses > 1year ago or
• • FSH and E2 levels in the postmenopausal range or
• • Patients who had bilateral ovariectomy (NCCN V.I. 2009)
• - Histologically confirmed ER+ locally advanced or metastatic breast cancer
• - Not eligible for curative therapy
• - Prior treatment with tamoxifen
• - Suitable to undergo endocrine treatment for ER+ ABC with SERD / sAI
• - Patient is able to read and understand German
• Exclusion Criteria:
• - Known hypersensitivity to Faslodex or Exemestane or any compounds of the drugs
• - Prior treatment with Faslodex 500 mg or Faslodex 250 mg*
• * for patients who receive treatment with Faslodex 500 mg within this observational study. Patients who are included in the exemestane arm may have received prior Faslodex treatment.
• - Prior treatment with Exemestane for patients who receive treatment with Exemestane within this observational study
• - Acutely life threatening disease
• - Treatment with Faslodex 250 mg/month (previously approved dose)
• - Prior palliative chemotherapy